Renal Anemia - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Anemia is a prevalent complication of chronic kidney disease (CKD), with its incidence increasing as the disease progresses. This condition significantly diminishes the quality of life and escalates morbidity and mortality among patients. Anemia is typically defined as a hemoglobin (Hb) level below 13 g/dL in men and below 12 g/dL in women, with Hb levels between 10 to 11 g/dL being more critical for clinical intervention. Anemia in CKD is characteristically normocytic, normochromic, and hyperproliferative.

In stable outpatients with CKD stage 3a (eGFR, 45-59) and 3b (eGFR, 30-44), approximately 42% exhibit Hb levels below 12 g/dL, whereas only about 6% have Hb levels below 10 g/dL. Most patients with CKD stage 3a and virtually all with stage 3b present with elevated serum creatinine. Among patients with stable CKD stage 4 (eGFR, 15-29), anemia is observed in roughly 54%, with about 11% having Hb levels below 10 g/dL. In stage 5 nondialysis patients (eGFR, <15), approximately 75% have anemia, and around 50% exhibit Hb levels below 10 g/dL. Anemia is almost universal in dialysis patients, with 90% requiring treatment with erythropoiesis-stimulating agents (ESAs).

Several factors contribute to anemia in CKD, with a primary cause being relative erythropoietin (EPO) deficiency. In CKD, serum EPO concentrations are generally normal or slightly increased but are inadequately low relative to the degree of anemia. Other contributors include:

• Uremic inhibitors.
• Inflammation.
• Shortened red blood cell survival.
• Nutritional deficiencies such as vitamin B12.

Inflammation is increasingly recognized as a significant factor complicating the diagnosis of iron deficiency (ID) in CKD-related anemia. It leads to elevated hepatic production of hepcidin. This acute-phase reactant increases serum ferritin levels and hinders iron absorption and release from macrophages, thus reducing iron availability for erythropoiesis. Additional contributors include increased intestinal blood loss and hyperparathyroidism, making the pathobiology of CKD-related anemia multifactorial.

The differential diagnoses for anemia in chronic renal disease include alcohol misuse disorder, aplastic anemia, dialysis complications, hypothyroidism, hyperthyroidism, methemoglobinemia, sickle cell anemia, systemic lupus erythematosus, hypoadrenalism, panhypopituitarism, primary and secondary hyperparathyroidism, and myelophthisic anemia.

Historically, blood transfusions were the primary treatment for anemia in CKD, but they posed numerous risks, including infections, hemosiderosis, fluid overload, and transfusion reactions. Contemporary treatment focuses on improving renal function and enhancing red blood cell production. ESAs, in conjunction with iron supplementation, are the preferred treatment for anemia in CKD. Recombinant human erythropoietin and darbepoetin alfa are the two ESAs commonly utilized in managing this condition.

The broad opportunity areas in renal anemia include,

Closing statement: Targeting these opportunities would help drug marketers capture substantial patient share in renal anemia and achieve commercial success.

Thelansis report on renal anemia provides in-depth insights into the disease and patient segments, along with the areas of unmet need and drug development pipeline. The report answers key questions such as,

• What is the epidemiology for renal anemia in the major markets, including the United States, Europe, Japan, China, and emerging markets?
• What are the estimated cases of anemia anemia in diagnosed and treated Populations?
• What are the drug treatment rates in renal anemia?
• What are the KOL opinions on the unmet need areas for drug development in renal anemia?
• What is the current and emerging competitive landscape in renal anemia?
• What is the current market size in terms of renal anemia sales?
• How will the landscape evolve over the next 10 years?

?

KOL

Erythropoiesis-stimulating agents (ESAs) and iron supplementation remain the cornerstone treatments for anemia in patients with chronic kidney disease (CKD). The consensus among experts affirms that hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are highly effective in correcting anemia and maintaining hemoglobin levels through a distinct mechanism compared to traditional ESAs. A-France-based-Hematologist

Ferumoxytol is expensive, but it is cost-effective for outpatients needing parenteral administration. This is due to its requirement for fewer doses and shorter administration times per dose. A-US-based-Urologist

?

About Thelansis

Thelansis specializes in pharmaceutical and biopharmaceutical business research and consulting Company, published reports across the therapeutic area, including both rare / ultra-rare and mainstream indications. Over the period, we have built a strong repository of 6,000+ bio-pharma reports covering epidemiology studies and market forecasting, as well as opportunity assessment based on the KOL interviews and conference coverage. Competitive intelligence and conference coverage throughout the phases of asset development executed by a team with a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

?

Offerings in the orphan indications: Syndicated reports/offerings for the major markets, epidemiology, customized market research including KOL interviews, PMR surveys, pipeline research, conference coverage, market forecast models, and consulting.

The developers and marketers of drugs in orphan indications can engage Thelansis for customized market research. They can gain possible solutions for ensuring considerable market penetration for their respective therapies.

?

For more information, please contact:

Ankit Sahoo

Email- [email protected]

Contact No: +91- 6397-349664